KMST.F Stock Overview
A biopharmaceutical company, develops regenerative medicine therapies based on cells derived from human embryonic stem cells to treat neuro-degenerative diseases.
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 0/6 |
| Dividends | 0/6 |
Kadimastem Ltd Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | ₪0.64 |
| 52 Week High | ₪0.64 |
| 52 Week Low | ₪0.64 |
| Beta | 0.49 |
| 11 Month Change | 0% |
| 3 Month Change | n/a |
| 1 Year Change | n/a |
| 33 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -8.23% |
Recent News & Updates
Recent updates
Shareholder Returns
| KMST.F | US Biotechs | US Market | |
|---|---|---|---|
| 7D | 0% | -1.3% | 3.9% |
| 1Y | n/a | 22.8% | 33.2% |
Return vs Industry: Insufficient data to determine how KMST.F performed against the US Biotechs industry.
Return vs Market: Insufficient data to determine how KMST.F performed against the US Market.
Price Volatility
| KMST.F volatility | |
|---|---|
| KMST.F Average Weekly Movement | n/a |
| Biotechs Industry Average Movement | 9.7% |
| Market Average Movement | 6.2% |
| 10% most volatile stocks in US Market | 15.4% |
| 10% least volatile stocks in US Market | 3.0% |
Stable Share Price: KMST.F has not had significant price volatility in the past 3 months.
Volatility Over Time: Insufficient data to determine KMST.F's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2008 | 12 | Asaf Shiloni | www.kadimastem.com |
Kadimastem Ltd, a biopharmaceutical company, develops regenerative medicine therapies based on cells derived from human embryonic stem cells to treat neuro-degenerative diseases. Its products in pipeline include AstroRx, a clinical grade human astrocytes that is in Phase 1/2a clinical trial for the treatment of amyotrophic lateral sclerosis and other neurodegenerative diseases; and IsletRx, a clinical grade pancreatic islet cell therapy treatment for diabetes. The company was incorporated in 2008 and is based in Ness Ziona, Israel.
Kadimastem Ltd Fundamentals Summary
| KMST.F fundamental statistics | |
|---|---|
| Market cap | US$5.54m |
| Earnings (TTM) | -US$3.21m |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio-1.7x
P/E RatioIs KMST.F overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| KMST.F income statement (TTM) | |
|---|---|
| Revenue | ₪0 |
| Cost of Revenue | ₪0 |
| Gross Profit | ₪0 |
| Other Expenses | ₪12.05m |
| Earnings | -₪12.05m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -2.87 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | -115.0% |
How did KMST.F perform over the long term?
See historical performance and comparison